MSCs overexpressing FGF21 alleviate acetaminophen-induced acute liver injury by eliciting macrophage-mediated phagocytosis Authors: Qian Huai, Cheng Zhu, Haoran Huang, Long Cheng, Xiaoqin Deng, Yue Wang, Tianyin Sun, Lijuan Mao, Yongkang Zhang, Mengwei Wu, Shi Yin, Hanren Dai, Xiaolei Li, Hua Wang Published: 2026 ABSTRACT Background:Acetaminophen (APAP) is a widely used analgesic and antipyretic agent that is safe at therapeutic doses. However, due to its extensive misuse, APAP-induced liver injury has become a major public health concern. Although mesenchymal stem/stromal cells (MSCs) represent a promising emerging therapy for APAP-induced liver injury, considerable research has focused on enhancing their efficacy, notably through genetic modification. Fibroblast growth factor 21 (FGF21), an endocrine hormone activated by metabolic stress, is known to regulate energy homeostasis, glucose and lipid metabolism, and to promote the homing of MSCs to sites of injury. Consequently, this study was designed to determine whether genetically engineering MSCs to overexpress FGF21 (FGF21-MSCs) augments their therapeutic potential against APAP-induced acute liver injury (ALI).Methods:In this investigation, MSCs were employed as a platform for FGF21 gene delivery. The MSCs were transduced with lentiviral vectors encoding the FGF21 gene to facilitate sustained FGF21 overexpression. We subsequently assessed the therapeutic potential of these FGF21-MSCs in a murine model of APAP-induced ALI. The extent of liver injury was comprehensively evaluated. Furthermore, the underlying mechanisms were elucidated using techniques including immunohistochemistry, immunofluorescence, and flow cytometry.Results:Our results demonstrated that FGF21-MSCs significantly enhanced the therapeutic efficacy of conventional MSCs against APAP-induced ALI via a biphasic mechanism: attenuating oxidative stress and inflammation during the acute injury phase, while actively fostering tissue repair during the subsequent regenerative phase. This protective effect is primarily mediated through the enhancement of macrophage phagocytic capacity, thereby accelerating tissue repair and regeneration.Conclusions:Our findings demonstrate that FGF21-MSCs significantly augment therapeutic efficacy against APAP-induced ALI in mice, thereby yielding critical insights and revealing novel therapeutic targets for ALI prevention and treatment. INTRODUCTION Acetaminophen (APAP) is a widely used analgesic and antipyretic agent that is safe at therapeutic doses.1 However, due to its extensive misuse, APAP-induced liver injury has become a major public health concern. According to 2020 data, APAP overdose is the most common cause of acute liver failure (ALF) in the United Kingdom and Europe, accounting for 40%–70% of all ALF cases.23 APAP-induced hepatotoxicity primarily progresses through 3 distinct phases.4 In the initial stage following overdose, APAP is rapidly metabolized into its active metabolite, N-acetyl-p-benzoquinone imine (NAPQI), which is subsequently detoxified via conjugation with glutathione (GSH), leading to a swift depletion of intracellular GSH reserves.5 Excessive NAPQI then forms covalent protein adducts, particularly within mitochondria, resulting in mitochondrial dysfunction and the generation of reactive oxygen species (ROS). The ensuing overproduction of ROS induces DNA damage and hepatocellular injury, characterized by centrilobular necrosis. During the progression phase, necrotic hepatocytes release endogenous damage-associated molecular patterns (DAMPs), such as HMGB1 and DNA fragments, which trigger the recruitment of inflammatory cells and the production of cytokines, thereby initiating sterile inflammation. In the recovery phase, compensatory proliferation of hepatocytes occurs, replacing necrotic cells with newly formed ones and facilitating hepatic regeneration. Despite our growing biological understanding of APAP-induced hepatotoxicity, the effective treatment of APAP-induced liver injury remains challenging. Hepatic macrophages include 2 major types of cells, liver-resident Kupffer cells and infiltrating monocyte-derived macrophages (MoMFs).6 Macrophages have a pronounced plasticity and adaptation potential following distinct liver injuries. Thus, many subsets of macrophages under different disease conditions may have diverse roles, ranging from beneficial to detrimental in various pathologies. APAP-induced liver injury is primarily characterized by massive hepatocyte necrosis following overdose. This persistent cell death elicits a robust pro-inflammatory response, prompting the infiltration and recruitment of inflammatory cells into the injured liver.7 APAP overdose induces rapid, extensive hepatic infiltration by monocytes, which then differentiate into MoMFs in situ. These early MoMFs are inflammatory (eg, Ly6Chigh) and exhibit poor phagocytic capacity during the early injury phase. However, the subsequent engulfment of necrotic hepatocytes by infiltrating Ly6Chigh macrophages induces a phenotypic switch to the Ly6Clow subset. This Ly6Clow phenotype is distinctly anti-inflammatory and tissue-protective during the resolution phase of APAP-induced liver injury.8 Accumulating evidence suggests that MoMFs transition phenotypically and functionally to promote effective wound healing and tissue regeneration. Specifically, a previous study also showed that the phenotypic conversion of pro-inflammatory Ly6ChiCX3CR1 lo monocytes/macrophages to reparative Ly6CloCX3CR1 hi macrophages promoted inflammation resolution and subsequent liver repair.9 Based on single-cell RNA sequencing and spatial transcriptomics, recent work identified distinct MoMF populations surrounding necrotic lesion areas. These cells express various proteins that promote dead cell debris clearance. Moreover, these necrotic lesion-associated macrophages are critical for promoting resolution in both acute and chronic liver injury.10 Although local tissue signals significantly influence macrophages' reprogramming, the specific microenvironmental cell types and molecular mechanisms that instruct this repair phenotype are not fully understood. Mesenchymal stem cells (MSCs) are multipotent stem cells capable of rapid proliferation as fibroblast-like, adherent cells under specific culture conditions in vitro. Given their capacity for mesodermal differentiation, low immunogenicity, and potent immunomodulatory properties, MSCs have emerged as promising therapeutic agents.11 Research has revealed that MSCs contribute to various acute and chronic liver disease processes through multiple mechanisms, including paracrine secretion of cytokines and growth factors that mediate immunomodulation, direct cellular interactions with injured cells, and transdifferentiation into hepatocytes.1213 In a murine model of APAP-induced ALF, MSCs mitigate hepatocyte necrosis through the secretion of hepatocyte growth factor (HGF). Furthermore, this protective effect demonstrates comparable efficacy to N-acetylcysteine (NAC), the only clinically approved drug currently available.14 While conventional, unmodified MSCs have been the primary focus of therapeutic investigations, recent research has increasingly explored strategies to enhance their efficacy.1516 These approaches include genetic engineering and in vitro preconditioning to improve their targeted homing capacity and survival rates. Genetically modified MSCs can enhance the protective effect against APAP-induced liver injury by activating the AMPK/SIRT pathway.17 Furthermore, modified MSCs serve as “Trojan horses” for the targeted delivery of cytokines, specifically TNF-related apoptosis-inducing ligand (TRAIL), type I interferons (IFNs), and interleukin-2 (IL-2).181920 Consequently, the diverse advancement of engineering methodologies in MSC-focused clinical applications is critical for enhancing innate functionalities, including immunomodulatory and regenerative capabilities, thereby broadening therapeutic potential and optimizing efficacy across various diseases. The therapeutic potential of MSCs is largely driven by their robust paracrine capacity and immunosuppressive effect on immune cells. This efficacy is underscored by findings that MSC-mediated macrophage phenotype modulation promotes fibrosis resolution. Specifically, MSC treatment facilitates the phenotypic shift from Ly6Chigh to Ly6Clow populations, concurrently suppressing the pro-inflammatory function of monocytes and enhancing the phagocytic function of MoMF.21 MSCs have therapeutic potential for acute liver injury (ALI) through their immunoregulation on macrophages, but the mechanism remains elusive due to the heterogeneity and controversy of liver macrophages. Fibroblast growth factor 21 (FGF21) functions as a stress-induced hormone that plays significant roles in regulating energy balance and lipid homeostasis through a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-klotho (KLB).22 Emerging evidence indicates that FGF21 also exerts therapeutic benefit in mitigating APAP-induced hepatotoxicity in murine models.2324 A previous study showed that marked FGF21 elevation following APAP overdose constitutes a compensatory, hepatoprotective mechanism, primarily via enhanced PGC-1α/Nrf2-mediated antioxidant capacity in the liver.25 Consistent with this finding, targeted delivery of FGF21 to the liver in a murine model of APAP-induced ALI significantly attenuated the oxidative damage and intracellular inflammation in hepatocytes.26 The therapeutic potential of both FGF21 and MSCs in APAP-induced liver injury has been extensively investigated; however, the efficacy of genetically engineered MSCs overexpressing FGF21 in this context remains incompletely characterized. We previously reported that FGF21-MSCs affect the immunosuppressive capacity and treatment efficacy of MSCs in alcohol-associated liver disease (ALD).27 Recently, we found that FGF21-MSCs exhibit a great therapeutic potential in mice with APAP-induced liver injury or ALF. Furthermore, we revealed that infusion of ex vivo expanded FGF21-MSCs significantly enhances the therapeutic efficacy of MSCs against APAP-induced liver injury through a dual-phase mechanism: mitigating oxidative stress and inflammation during the acute injury phase, while promoting tissue repair during the regenerative phase. The underlying mechanism appears to involve enhanced macrophage phagocytic capacity, thereby facilitating tissue repair and regeneration. Our data suggest that MSCs modification by FGF21 could enhance their protective effect in APAP-induced liver injury via macrophage-mediated phagocytosis and may help in the exploration of effective MSC-based cell therapies for the treatment of APAP-induced ALI. METHODS Animal models Male C57BL/6J wild-type (WT) mice aged 8-9 weeks were purchased from Gempharmatech (Nanjing, China). All animal experiments were approved by the Animal Ethics Committee of Anhui Medical University. The study adhered to the Declaration of Helsinki and was approved under the project, entitle “Mechanistic investigation of human umbilical cord mesenchymal stem cells ameliorating drug-induced acute liver injury” (No. LLSC20252163). The mice were housed in a pathogen-free and temperature-regulated facility with a 12-hour light–dark cycle. Animals had free access to a standard rodent diet and sterilized drinking water during the study. Mice were fasted overnight (ie, for ~16 h) before APAP (Sigma-Aldrich, St. Louis, MO, USA) administration. A total of 25 mg/mL APAP solution was freshly prepared by dissolving APAP in sterile saline. Then the solution was intraperitoneally (i.p.) injected into mice at a dose of 300 mg/kg to induce hepatoxicity or 600 mg/kg to induce ALF. Mice received sterile saline as a control. For pre-injection treatment, MSCs or FGF21-MSCs (5×105 cells per mouse) were administered to mice via the tail vein 2 hours before APAP treatment. For therapeutic treatment, MSCs or FGF21-MSCs were administered to mice via the tail vein 2 hours after APAP treatment. All MSCs were used within 5–8 passages in the experiments. To evaluate the therapeutic potential of FGF21-MSCs in APAP-induced liver injury, recombinant human FGF21 protein (2 mg/kg) (MedChemExpress, New Jersey, USA) was administered to mice 2 hours after APAP treatment. NAC (500 mg/kg) (Selleck, Shanghai, China) was administered 2 hours after APAP injection. At the indicated time points, the mice were sacrificed, and samples of blood and liver tissue were collected for subsequent biochemical and histologic analysis. Isolation and culture of bone marrow-derived macrophages As previously described,2829 to obtain bone marrow-derived macrophages (BMDMs), bone marrow cells were isolated from the femur and tibia of C57BL/6 mice. After washing, the cell suspension was filtered through a 70 μm cell strainer and plated in a 6-well plate at a density of 2×106 with macrophage colony-stimulating factor (M-CSF, 40 ng/mL) in high-glucose Dulbecco modified Eagle medium (DMEM)/F12 supplemented with of 10% fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 mg/mL of streptomycin (PS). The freshly prepared medium with supernatant derived from MSCs (medium: supernatant = 2:1) was replenished on days 3 and 6. Biochemistry and enzyme-linked immunosorbent assay Blood samples were collected and centrifuged (3500 rpm, 10 min) to obtain serum. Serum levels of ALT were measured by using a commercial alanine aminotransferase assay kit (Shenzhen Mindray Biomedical Electronics Co., Ltd., Shenzhen, China) according to the manufacturer’s instructions. Liver tissues were homogenized and analyzed for GSH, SOD, and MDA (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) using corresponding commercial kits. Serum concentrations of FGF21 (ELK Biotechnology Co., Ltd., Wuhan, China) were quantified using ELISA kits. Statistical analysis The results were presented as mean ± standard error of the mean, and all statistical analyses were analyzed using GraphPad Prism software version 9.0 (GraphPad, San Diego, CA, USA). Data were compared by the application of an unpaired two-tailed Student t test and one-way analysis of variance (ANOVA) or two-way ANOVA. Differences with p values <0.05 were considered statistically significant among groups. Additional methods Additional materials and methods for MSCs and the culture supernatants preparation, AML12 hepatocytes culture, histopathological and immunohistochemical staining, TUNEL assay, phagocytosis assays, RT-qPCR, Western Blot, RNA sequencing and analysis, Flow cytometry, and primer sequences for RT-qPCR analysis (Supplemental Table 1 https://links.lww.com/HC9/C452) are available in Supplemental Materials and Methods, https://links.lww.com/HC9/C452. RESULTS Functional profile and homing capacity of FGF21-MSCs in APAP-challenged mice MSCs were isolated from human umbilical cords using the tissue explant method (Figure 1A). Cells exhibited typical fibroblast-like morphology and adhered to the plastic surface (Figure 1B). FGF21-MSCs were engineered via lentiviral vector-mediated overexpression of FGF21. The transduction efficiency was confirmed as previously described.27 Flow cytometry analysis confirmed that FGF21-MSCs were positive for CD90, CD105, and negative for CD19, CD34, and CD45, which was consistent with typical MSCs (Figure 1C). To investigate the impact of FGF21 overexpression on the transcriptional profile of MSCs, we performed RNA sequencing (RNA-seq) on FGF21-MSCs and vector-MSCs. We observed a significant upregulation of genes associated with immunomodulation, anti-inflammation, and tissue repair in the FGF21-MSC group (Figure 1D). These findings were subsequently validated by RT-qPCR (Figure 1E). To assess the homing of transplantation MSCs in vivo, we injected DiR-labeled MSCs or FGF21-MSCs into liver-injured mice through the tail vein. In vivo imaging results revealed a significant accumulation of MSCs in the livers of mice with APAP-induced liver injury, with the FGF21-MSC group exhibiting the most pronounced enrichment (Figure 1F). Furthermore, our results demonstrate that this increased hepatic homing of FGF21-MSCs is injury-dependent (Supplemental Figure S1A, https://links.lww.com/HC9/C452). Collectively, these findings indicate that genetic engineering enhances the expression of beneficial factors in the MSC secretome and improves in vivo homing following liver injury, without compromising their intrinsic properties. Functional characteristics and in vivo homing of FGF21-MSCs in APAP-induced mice. (A) Isolation and culture of human umbilical cord-derived mesenchymal stromal/stem cells (hUC-MSCs). (B) The morphology of MSCs (left) and FGF21-MSCs (right). Scale bar: 200 μm. (C) Flow cytometry analysis confirmed that FGF21-MSCs were positive for CD90 and CD105, and negative for CD19, CD34, and CD45. (D) Heatmap showing the differential expression of genes related to inflammation regulation and tissue repair between FGF21-MSCs and Vector-MSCs. (E) The mRNA levels of PGE2, IDO1, TSG-6, IL-10, and HGF in Vector-MSCs and FGF21-MSCs. (F) In vivo biodistribution of DiR-labeled MSCs in APAP-injured mice at different time points (n=4). Data are shown as mean ± SEM, *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Statistical significance was assessed by an unpaired two-tailed Student t test. Abbreviations: APAP, acetaminophen; FGF21, fibroblast growth factor 21; HGF, hepatocyte growth factor; hUC-MSCs, human umbilical cord-derived mesenchymal stromal/stem cells; IDO1, indoleamine 2,3-dioxygenase 1; IL-10, interleukin-10; NC, negative control; PGE2, prostaglandin E2; TSG-6, tumor necrosis factor-inducible gene 6 protein. Efficacy evaluation of FGF21-MSCs in APAP-induced liver injury To investigate the role of MSCs or FGF21-MSCs in ALI, mice were pre-treated with MSCs or FGF21-MSCs via tail vein injection 2 hours before APAP administration (Figure 2A). Following the APAP challenge, a marked elevation in the liver function marker ALT was observed compared with the saline control group. Consistent with previous findings,30 infusion of MSCs partially attenuated APAP-induced ALI, while administration of FGF21-MSCs significantly potentiated this protective effect beyond that of naïve MSCs (Figure 2B). In addition, we administered MSCs or FGF21-MSCs via tail vein injection 2 hours after APAP exposure (Figure 2C). FGF21-MSC treatment significantly improved liver function, as evidenced by reduced serum ALT levels (Figure 2D). Centrilobular necrosis, a key pathological hallmark of APAP-induced hepatocyte death, was examined through hematoxylin and eosin (H&E) staining and quantitative analysis of necrotic area. These results demonstrated that pretreatment with FGF21-MSCs substantially enhanced the capacity of MSCs to counteract APAP-induced hepatotoxicity (Figures 2E, F). Additional assessment through TUNEL staining indicated that FGF21-MSC pretreatment markedly reduced the number of TUNEL-positive cells (Figures 2G, H). Histopathological analysis of liver tissues at 24 and 72 hours post-APAP challenge demonstrated that FGF21-MSC administration post-APAP injection markedly enhanced the therapeutic efficacy of MSCs, with significantly diminished necrotic area compared with the naïve MSC group (Figures 2I–L) without compromising the safety of other organs (Supplemental Figures S2A–D, https://links.lww.com/HC9/C452). Thus, these findings demonstrate that FGF21-MSC administration significantly enhances the therapeutic efficacy of MSCs against APAP-induced liver injury. FGF21-MSCs enhance the hepatoprotective efficacy of MSCs against APAP-induced liver injury. (A) Schematic of the experimental process. Mice fasted for 16 hours were injected with APAP (300 mg/kg, i.p.) to induce ALI. A single dose of MSCs or FGF21-MSCs 2 hours prior to APAP challenge. (B) Serum level of ALT in each group (n=6). (C) Schematic of the experimental process. Mice fasted for 16 hours were injected with APAP (300 mg/kg, i.p.) to induce ALI. A single dose of MSCs or FGF21-MSCs 2 hours after APAP challenge. (D) Serum level of ALT in each group (n=6). (E) Representative H&E staining of the liver sections from each group (n=6). Scale bar: 200 μm. (F) Quantification of necrotic area. (G) TUNEL staining of liver tissue from each group. Scale bar: 200 μm. (H) Quantifications of TUNEL-positive cells from (G). (I) Representative H&E staining of the liver sections from each group (n=6). The mice were administered APAP for 24 hours. Scale bar: 200 μm. (J) Quantification of necrotic area from (I). (K) Representative H&E staining of the liver sections from each group (n=6). The mice were administered APAP for 72 hours. Scale bar: 200 μm. (L) Quantification of necrotic area from (K). Data are shown as mean ± SEM (n=4–6). *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001. Statistical significance was assessed by one-way ANOVA. Abbreviations: ALI, acute liver injury; ALT, alanine aminotransferase; APAP, acetaminophen; FGF21, fibroblast growth factor 21; H&E, hematoxylin and eosin; MSCs, mesenchymal stromal/stem cells. FGF21-MSCs mitigate hepatic inflammatory infiltration and reestablish redox homeostasis The inflammatory response plays a critical exacerbating role in APAP-induced ALI.31 We first assessed the populations of liver-infiltrating macrophages and neutrophils, 2 major types of inflammatory cells recruited to the damaged liver. Immunohistochemical analysis of F4/80 and Ly6G in liver tissues revealed a significant increase in F4/80-positive macrophages 24 hours after APAP challenge, although no statistically significant differences were observed among treatment groups. Similarly, Ly6G-positive neutrophil infiltration was markedly elevated following APAP administration. While pretreatment with MSCs moderately attenuated neutrophil infiltration, FGF21-MSC pretreatment resulted in a substantially greater reduction in hepatic Ly6G-positive neutrophils compared with naïve MSCs (Figures 3A, B). Consistent results were also obtained from MPO staining (Supplemental Figures S3A, B, https://links.lww.com/HC9/C452). Furthermore, RT-qPCR analysis demonstrated that FGF21-MSC pretreatment significantly attenuated the mRNA expression of key inflammatory mediators (Tnf-α, Il-1β, Cxcl1, Ccl2) in liver tissue (Figure 3C). Given that oxidative stress represents another hallmark of APAP hepatotoxicity, biochemical assays demonstrated that FGF21-MSC administration restored hepatic GSH and superoxide dismutase (SOD) levels while reducing malondialdehyde (MDA) content (Figure 3D), indicating a crucial role in reestablishing redox homeostasis. It is noteworthy that MSC and FGF21-MSC pretreatment did not alter CYP2E1 expression or activity, but most likely conferred antioxidant protection by accelerating the compensatory replenishment of GSH (Supplemental Figures S4A–C, https://links.lww.com/HC9/C452). Similarly, consistent results were obtained when MSCs or FGF21-MSCs were administered 2 hours post-APAP injection (Figures 3E–H). Collectively, these findings indicate that FGF21-MSCs play a pivotal role in modulating inflammatory responses and restoring hepatic redox homeostasis during the acute phase of APAP-induced liver injury. FGF21-MSCs modulate immune responses and reestablish redox homeostasis. (A) Representative images of immunostaining of F4/80-positive macrophages/Kupffer cells and Ly6G staining of infiltrated neutrophils in the livers of each group of mice. A single dose of MSCs or FGF21-MSCs 2 hours prior to APAP challenge. The mice were administered APAP for 24 hours. Scale bar: 200 μm. (B) Quantifications of F4/80-positive and Ly6G-positive area from (A). (C) Hepatic mRNA levels of Tnf-α, Il-1β, Cxcl1, and Ccl2 were measured by RT-qPCR in mice. (D) Hepatic levels of GSH, SOD, and MDA in APAP-ALI mice with indicated treatments. (E) Representative images of immunostaining of F4/80-positive macrophages/Kupffer cells and Ly6G staining of infiltrated neutrophils in the livers of each group of mice. A single dose of MSCs or FGF21-MSCs 2 hours after APAP challenge. The mice were administered APAP for 24 hours. Scale bar: 200 μm. (F) Quantifications of F4/80-positive and Ly6G-positive area from (E). (G) Hepatic mRNA levels of Tnf-α, Il-1β, Cxcl1, and Ccl2 were measured by RT-qPCR in mice. (H) Hepatic levels of GSH, SOD, and MDA in APAP-ALI mice with indicated treatments. The mice were administered APAP for 24 hours. Data are shown as mean ± SEM (n=4–6). *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001; ns, no significance. Statistical significance was assessed by one-way ANOVA. Abbreviations: ANOVA, analysis of variance; APAP, acetaminophen; APAP-ALI, APAP-induced acute liver injury; Ccl2, C-C motif chemokine ligand 2; Cxcl1, C-X-C motif chemokine ligand 1; FGF21, fibroblast growth factor 21; GSH, glutathione; Il-1β, interleukin-1β; MSCs, mesenchymal stromal/stem cells; MDA, malondialdehyde; RT-qPCR, quantitative reverse transcription PCR; SOD, superoxide dismutase; Tnf-α, tumor necrosis factor α. FGF21-MSCs improve survival and promote liver repair and regeneration in APAP-challenged mice Hepatic repair and regeneration represent a crucial phase in the pathological progression of APAP-induced ALI.32 To investigate whether FGF21-MSC pretreatment influences the regenerative phase, we analyzed liver tissues collected 72 hours post-APAP challenge (Supplemental Figure S5A, https://links.lww.com/HC9/C452). Assessment of serum ALT levels (Supplemental Figure S5B, https://links.lww.com/HC9/C452) and histological examination via H&E staining (Supplemental Figures S5C, D, https://links.lww.com/HC9/C452) demonstrated that FGF21-MSC pretreatment significantly enhanced hepatic recovery, with both MSC and FGF21-MSC groups showing reduced necrotic areas, particularly in the FGF21-MSC group. Immunohistochemical analysis of inflammatory cell infiltration revealed that FGF21-MSC pretreatment substantially decreased Ly6G-positive neutrophil accumulation, while F4/80-positive macrophage numbers remained comparable across groups—consistent with observations at 24 hours (Supplemental Figures S5E, F, https://links.lww.com/HC9/C452). Furthermore, in a model of ALF induced by a high dose of APAP (600 mg/kg), both MSC pretreatment and immediate NAC administration reduced mortality. Remarkably, FGF21-MSC pretreatment conferred a significantly greater survival advantage over naïve MSCs (Figures 4A, B). These findings were further corroborated by the gross appearance of the liver and H&E histological examination (Supplemental Figures S6A–C, https://links.lww.com/HC9/C452). In addition, FGF21-MSC treatment 2 hours post-APAP challenge substantially improved survival rates compared with conventional MSC therapy (Figure 4C-D). Staining for the proliferation marker Ki-67 indicated that FGF21-MSC treatment markedly enhanced hepatocyte proliferation compared with naïve MSCs, with this effect being more pronounced at the 72-hour time point (Figures 4E–J). In vitro CCK-8 assays confirmed that this pro-proliferative effect was not directly mediated by rhFGF21 at the corresponding time point (Figure 4K). Collectively, these results indicate that FGF21-MSCs augment regenerative repair following APAP-induced liver injury. FGF21-MSCs improve survival and regenerative repair following APAP-induced liver injury. (A) Schematic of the experimental process. Mice treated with MSCs or FGF21-MSCs 2 hours prior to and with NAC 2 hours post-APAP (600 mg/kg) challenge. (B) Survival curve of mice treated with MSCs or FGF21-MSCs 2 hours prior to and with NAC 2 hours post-APAP (600 mg/kg) challenge (n=10–16). (C) Schematic of the experimental process. Mice were treated with MSCs or FGF21-MSCs 2 hours after APAP (600 mg/kg) challenge. (D) Survival curve of mice treated with MSCs or FGF21-MSCs 2 hours APAP (600 mg/kg) challenge (n=10–16). (E) Hepatocyte proliferation was assessed by anti-Ki-67 immunohistochemical staining of liver tissue sections from each group. The mice were administered APAP for 24 hours. Scale bar: 200 μm. (F) Quantifications of Ki-67(+) hepatocytes per high power field (HPF) from (E). (G) Hepatocyte proliferation was assessed by anti-Ki-67 immunohistochemical staining of liver tissue sections from each group. The mice were administered APAP for 72 hours. Scale bar: 200 μm. (H) Quantifications of Ki-67(+) hepatocytes per high power field (HPF) from (G). (I) Hepatocyte proliferation was assessed by anti-Ki-67 immunohistochemical staining of liver tissue sections from each group. A single dose of MSCs or FGF21-MSCs 2 hours after APAP challenge. The mice were administered APAP for 72 hours. Scale bar: 200 μm. (J) Quantifications of Ki-67(+) hepatocytes per high power field (HPF) from (I). (K) AML12 were treated with rhFGF21(1 μg/mL) for different durations, and cell proliferation was determined by CCK-8 assay. Data are shown as mean ± SEM (n=4–6). *p<0.05, **p<0.01, and ***p<0.001; ns, no significance. Statistical significance was assessed by one-way ANOVA. Abbreviations: ANOVA, analysis of variance; APAP, acetaminophen; FGF21, fibroblast growth factor 21; HPF, per high power field; MSCs, mesenchymal stromal/stem cells; NAC, N-acetylcysteine; rhFGF21, recombinant human FGF21 protein. FGF21-MSCs exhibit superior therapeutic efficacy compared with rhFGF21 in APAP-induced liver injury Previous studies have documented the hepatoprotective effects of recombinant FGF21 administration in mice with APAP-induced ALI.26 To comparatively evaluate the therapeutic efficacy of FGF21-MSCs versus exogenous recombinant human FGF21 (rhFGF21), we administered respective treatments via tail vein injection 2 hours post-APAP challenge (Figure 5A). Consistent with prior reports, rhFGF21 treatment attenuated hepatic injury as reflected by reduced ALT levels, while FGF21-MSC infusion produced significantly greater improvement in ALT elevation compared with the rhFGF21 group (Figure 5B). Histopathological analysis of liver tissues at 24 and 72 hours post-APAP revealed that FGF21-MSC administration substantially reduced the necrotic area compared with rhFGF21 treatment alone (Figures 5C–F). Biochemical assays demonstrated that FGF21-MSC treatment more effectively restored hepatic GSH and SOD levels while reducing MDA content relative to the rhFGF21 group (Figure 5G). ELISA analysis of serum human FGF21 levels at 24 hours post-APAP confirmed the expected elevation in the rhFGF21-treated group, while FGF21-MSC administration maintained substantially higher circulating FGF21 levels compared with bolus rhFGF21 injection (Figure 5H). Consistent with our previous in vitro findings, Ki-67 staining revealed that rhFGF21 treatment did not increase the number of Ki-67-positive hepatocytes at 24 and 72 hours post-APAP challenge compared with the APAP-alone group. Furthermore, the number of Ki-67-positive hepatocytes in the rhFGF21 treatment group was significantly lower than that in the FGF21-MSC group (Supplemental Figures S7A, B, https://links.lww.com/HC9/C452). These findings suggest the superior therapeutic efficacy of FGF21-MSCs over recombinant FGF21 may be attributed to sustained release of rhFGF21 from engrafted cells in vivo. FGF21-MSCs exhibit superior therapeutic efficacy compared with rhFGF21 in APAP-induced liver injury. (A) Schematic of the experimental process. (B) Serum level of ALT in each group (n=6). (C) Representative H&E staining of the liver sections from each group (n=6). The mice were administered APAP for 24 hours. Scale bar: 200 μm. (D) Quantification of necrotic area from (C). (E) Representative H&E staining of the liver sections from each group (n=6). The mice were administered APAP for 72 hours. Scale bar: 200 μm. (F) Quantification of necrotic area from (E). (G) Hepatic levels of GSH, SOD, and MDA in APAP-ALI mice with indicated treatments. The mice were administered APAP for 24 hours. (H) Serum of hFGF21 level in APAP-ALI mice with indicated treatments. Data are shown as mean ± SEM (n=4–6). *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001; ns, no significance. Statistical significance was assessed by one-way ANOVA. Abbreviations: ALT, alanine aminotransferase; ANOVA, analysis of variance; APAP, acetaminophen; APAP-ALI, APAP-induced acute liver injury; FGF21, fibroblast growth factor 21; GSH, glutathione; H&E, hematoxylin and eosin; MDA, malondialdehyde; MSCs, mesenchymal stromal/stem cells; SOD, superoxide dismutase; rhFGF21, recombinant human FGF21 protein. FGF21-MSCs enhance the phagocytic capacity of BMDMs toward necrotic or apoptotic cells in vitro Macrophages play pivotal roles in both physiological tissue remodeling and pathological conditions involving inflammation and tissue injury.1033 The phagocytosis-mediated phenotypic shift of hepatic macrophages has been reported to accelerate the resolution of liver inflammation and facilitate liver repair and regeneration in APAP-induced liver injury. Our previous transcriptomic sequencing data suggested that FGF21-MSCs may exert immunomodulatory effects by influencing macrophage phenotypic polarization.27 Indeed, when BMDMs were treated with FGF21-MSC-conditioned medium (FGF21-MSCs-sup), significant alterations were observed in pathways related to chemokine signaling, cytokine regulation, and inflammatory responses. This prompted us to investigate whether macrophage phenotype was altered despite the absence of quantitative changes in hepatic macrophage populations across treatment groups following APAP injury. Transcriptomic analysis revealed that FGF21-MSCs-sup treatment significantly upregulated genes associated with phagocytic function (Figures 6A, B), a finding validated by RT-qPCR (Figure 6C). Using fluorescent bioparticles and CFSE-labeled apoptotic cells to assess phagocytic capacity, we demonstrated that while rhFGF21 moderately enhanced BMDM phagocytosis, FGF21-MSCs-sup treatment substantially augmented this effect (Figures 6D, E). Flow cytometric analysis confirmed these findings, showing significantly increased phagocytosis (FITC-positive cell percentage) in BMDMs treated with FGF21-MSCs-sup (Figures 6F, G). Furthermore, in an apoptosis clearance assay using dexamethasone-induced apoptotic thymocytes from male mice aged 3–4 weeks, both rhFGF21 and FGF21-MSCs-sup enhanced BMDM phagocytosis of apoptotic cells (Cd11b+FITC+ population), with FGF21-MSCs-sup producing markedly superior effects (Figures 6H, I). We performed in vitro loss-of-function experiments using UNC2250, a highly specific MerTK inhibitor. Strikingly, pharmacological blockade of MerTK effectively abrogated the FGF21-MSC-mediated enhancement of macrophage phagocytosis (Figures 6H, I). These results strongly suggest that the MerTK signaling pathway is indispensable for the improved clearance capacity observed in our model. Together, these results indicate that FGF21-MSCs promote tissue repair by modulating macrophage functional phenotype, particularly through enhancing phagocytic capacity for efficient clearance of necrotic debris. FGF21-MSCs enhance the phagocytic capacity of BMDMs toward necrotic or apoptotic cells in vitro. (A) Schematic of the experimental process. (B) Gene expression heatmap of genes involved in phagocytosis in BMDMs. (C) The mRNA levels of phagocytosis-related genes in BMDMs following the indicated condition. (D) Representative confocal immunofluorescence showing phagocytic uptake of bioparticles (up) and apoptotic cells (down) by BMDMs. Bioparticles (pHrodo, green), membrane (CellMask, red), apoptotic cells (CFSE, green), cytoskeleton (TRITC, red), and nuclei (DAPI, blue). Scale bar: 50 μm. (E) Phagocytosis quantification from (D). (F) Uptake of bioparticles (FITC) by BMDMs with indicated treatment was examined by flow cytometry. (G) Phagocytosis quantification in BMDMs with indicated treatment. (H) Representative flow plots showing phagocytic activity of BMDMs with indicated treatment after co-culture with PKH67 (FITC)-labeled apoptotic thymocytes. (I) Phagocytosis quantification in BMDMs incubated with PKH67-labeled apoptotic thymocytes for 2 hours. Data are shown as mean ± SEM. *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001; ns, no significance. Statistical significance was assessed by one-way ANOVA or two-way ANOVA (C). Abbreviations: ANOVA, analysis of variance; APAP, acetaminophen; BMDMs, bone marrow-derived macrophages; FGF21, fibroblast growth factor 21; MSCs, mesenchymal stromal/stem cells. DISCUSSION This novel investigation explores the therapeutic potential of genetically engineered mesenchymal stem cells overexpressing FGF21 (FGF21-MSCs) in enhancing treatment efficacy for APAP-induced liver injury in mice. By elucidating the novel mechanism through which FGF21-MSCs modulate the hepatic immune microenvironment and orchestrate tissue repair and regeneration following acetaminophen-induced ALI, this study provides crucial insights and unveils novel therapeutic targets for ALI prevention and treatment. The strategic genetic engineering of MSCs to overexpress FGF21 leverages the synergistic therapeutic effects of both components, enabling FGF21-MSCs to exert a dual-phase mechanism of action during distinct stages of APAP-induced liver injury—combating oxidative stress and inflammation in the acute phase while promoting tissue repair during the regenerative phase (Figure 7). These findings underline the significance of FGF21 signaling as a potential therapeutic target in APAP-induced liver injury, and it provides a possible strategy of novel MSC-based cell therapy for the clinical treatment of APAP-induced ALI. Genetically engineered MSCs enhance their protective effects against acetaminophen-induced liver injury. Briefly, the administration of in vitro-expanded FGF21-MSCs significantly augmented the therapeutic efficacy of MSCs in APAP-induced liver injury, demonstrating biphasic mechanisms of FGF21-MSCs at different stages of APAP-induced liver injury in mice: antioxidant and anti-inflammatory effects during the acute injury phase, and pro-repair effects during the repair and regeneration phase. Mechanistically, this enhancement could be associated with improved phagocytic capacity of macrophages, thereby promoting tissue repair and regeneration. Abbreviations: APAP, acetaminophen; FGF21, fibroblast growth factor 21; GSH, glutathione; IL, interleukin; MSCs, mesenchymal stromal/stem cells; SOD, superoxide dismutase; TNF-α, tumor necrosis factor α. NAC is still the only FDA-approved antidote against APAP overdose in clinical patients for over 4 decades. Despite its efficacy in most overdose cases, NAC has limited beneficial effects in late-presenting patients or those suffering massive overdoses, and delayed NAC treatment beyond the injury phase may impede hepatic regeneration.34 Other treatments need to be developed for patients with APAP overdose-induced ALF at later stages, and stem cell therapy is a potentially important treatment. MSCs are a type of multipotent adult stem cell that have significant advantages due to their ease of acquisition from different sources. MSCs effectively attenuate APAP-induced liver injury by inhibiting oxidative stress, inflammatory response, hepatocyte necrosis, and promoting liver regeneration in mice, which is a promising alternative for liver transplantation in treating early and late stages of APAP-induced ALF.35 However, the suboptimal therapeutic potential of naïve MSCs underscores the need to bolster their immunomodulatory capability. In the end, gene modification is considered a strategy for augmenting the therapeutic benefits of transplanted MSCs. In our previous study, we successfully constructed MSCs overexpressing FGF21 using a lentivirus vector without altering their intrinsic biological properties. In addition, we described a critical role for FGF21-MSCs in ALD, linked to macrophage polarization. The results, together with the established role of monocytes and macrophages in ALF pathogenesis, prompted us to investigate the impact of FGF21-MSCs on these cell populations in APAP-induced ALF. Following the analysis of transcriptome sequencing data, we found that treatment with FGF21-MSCs-sup significantly upregulated several genes related to macrophage phagocytosis, which was subsequently validated by RT-qPCR. This led us to hypothesize that FGF21-MSCs promote tissue repair and regeneration by influencing the functional phenotype of liver macrophages, enhancing their phagocytic ability to clear necrotic cells. Furthermore, in vitro experiments confirmed that FGF21-MSCs-sup could enhance the phagocytic capacity of BMDMs. Our results strongly suggest that FGF21-MSCs are promising to serve as a potential cell-based therapy for APAP-induced liver injury. FGF21 is widely recognized as a stress-responsive cytokine that regulates energy homeostasis in various preclinical studies. FGF21 is an atypical member of the FGF21 family that FGF21 can enter the circulation and exert effects on multiple organs and tissues. Accumulating evidence has indicated that FGF21 plays a crucial role in regulating inflammatory responses, in addition to its function in maintaining energy balance through the regulation of glucose and lipid metabolism.36 A previous study showed that FGF21 suppresses the inflammatory response by modulating the activation of macrophages via NF-κB and PPAR-γ signaling pathways.37 In addition, FGF21 can also promote macrophage phagocytosis to exert anti-inflammatory effects in a dose-dependent manner in vitro experiments.38 Supporting this, Zhu et al recently reported that FGF21 ameliorates septic liver injury by restraining the initiation and propagation of inflammation. Importantly, treatment with exogenous rhFGF21 effectively suppressed pro-inflammatory macrophage activation through the autophagy/HIF-1α axis.39 Herein, we demonstrate that FGF21-MSCs attenuate APAP-induced liver injury by counteracting oxidative stress and sterile inflammation, 2 central pathological drivers of ALF pathogenesis. Our study demonstrated that pretreatment of FGF21-MSCs significantly enhanced the hepatoprotective efficacy of MSCs against APAP-induced liver injury. This was evidenced by reduced hepatocyte death, decreased recruitment and infiltration of inflammatory cells in the liver, improved survival rates, and restoration of hepatic enzyme homeostasis. Moreover, FGF21-MSC infusion markedly potentiated the therapeutic efficacy of MSCs in APAP-induced liver injury. Administration of FGF21-MSCs either before or after APAP challenge demonstrated beneficial effects in animal models of APAP overdose. This significantly broadens the therapeutic window and creates conditions for application in various future clinically relevant scenarios. By using immunohistochemical Ki-67 staining, we evaluated the effect of FGF21-MSCs on liver regeneration in injured liver tissue and found that they significantly enhanced liver regeneration in APAP-induced liver damage. In vitro experiments indicated that this effect was not directly mediated by FGF21 to promote hepatocyte proliferation, which is consistent with a previous study.40 Furthermore, compared with single-dose rhFGF21 injection, FGF21-MSCs exhibited superior therapeutic efficacy in APAP-induced liver injury. We speculate that this may be attributed to the short half-life of rhFGF21 in mice. FGF21-MSCs act as an in vivo “bio-factory.” Their ability to home to the injured liver and continuously secrete FGF21 ensures a sustained therapeutic concentration at the local injury site. This prolonged exposure is crucial for driving the phenotypic switch of macrophages during the transition from the acute inflammatory phase to the reparative phase, which a single bolus of rhFGF21 fails to achieve. In addition, in vitro experiments revealed that macrophages mediated by FGF21-MSCs efficiently engulf necrotic debris, which contributed to phagocytosis-induced polarization of the macrophages toward a resolving phenotype. However, further work is needed to demonstrate its mechanism of effect on enhanced phagocytosis of dead hepatocytes by macrophages in APAP-challenged liver in mice. Macrophages regulate the progression and resolution of ALI through both innate immunological function and paracrine activity. As we all know, the differentiation of these macrophages into 2 major subsets, Ly6Chigh and Ly6Clow, induces opposite phenotypes in response to various stimuli. Generally, Ly6Chigh macrophages typically exhibit a pro-inflammatory phenotype, expressing high levels of pro-inflammatory factors and M1 markers; conversely, Ly6Clow macrophages adopt an anti-inflammatory profile, characterized by elevated expression of phagocytosis-related genes and M2 markers.41 The literature is conflicting on the role of macrophages in the pathogenesis of APAP-induced liver injury. Specifically, one study reported that macrophages exacerbate APAP-induced inflammation by releasing IL-1α, which is able to chemoattract and activate CD11b+Gr-1+ myeloid cells.42 However, recent evidence showed that alternatively activated macrophages reduced inflammatory mediators and promoted hepatocyte proliferation in the injured liver, owing to their acquired high phagocytic capacity.43 The plasticity of macrophage phagocytosis is increasingly recognized across diverse liver diseases, including metabolic dysfunction–associated steatotic liver disease, hepatocellular carcinoma, ischemia-reperfusion injury, and toxicant-induced or drug-induced ALI. Macrophage phagocytosis is a specific cellular process that is mediated by ligand–receptor interactions between target cells and macrophages, which encompasses the recognition, binding, internalization, and digestion of dead cells.444546 The process is regulated by the integration of opposing “eat-me” signals (eg, calreticulin) and “don’t-eat-me” signals (eg, CD47), through their respective receptors, which collectively determine the phagocytic outcome. For example, MerTK (Mer), a key phagocytosis receptor and member of the Axl-Mer-Tyro3 receptor tyrosine kinases family, is expressed primarily on macrophages.47 In an acute-on-chronic liver failure mouse model, MSCs improved liver function and alleviated inflammatory injury via promoting M2 macrophage polarization and elevating macrophage Mertk expression.48 Similarly, MERTK+ macrophages are associated with enhanced clearance of apoptotic cells and the suppression of inflammatory response in patients with APAP-induced ALF.49 In our previous study, we observed that FGF21-MSCs induce a shift in macrophage phenotype towards an anti-inflammatory profile. Subsequently, we demonstrated that FGF21-MSCs potentiate the ability of macrophage phagocytosis, which confers them pro-resolution features in the current study. Yet, the role of phagocytosis-related receptors in FGF21-MSC-mediated phagocytosis remains incompletely elucidated at the molecular level. While our initial transcriptomic and in vitro data demonstrated that FGF21-MSCs potentiate macrophage phagocytosis to confer pro-resolution features, the specific molecular executioners remained to be fully elucidated. MerTK, a prominent member of the Axl-Mer-Tyro3 receptor tyrosine kinase family, is a critical receptor mediating the recognition and engulfment of apoptotic and necrotic cells. To functionally validate its involvement, we performed in vitro loss-of-function experiments using UNC2250, a highly specific MerTK inhibitor. Strikingly, pharmacological blockade of MerTK effectively abrogated the FGF21-MSC-mediated enhancement of macrophage phagocytosis. These results strongly suggest that the MerTK signaling pathway is indispensable for the improved clearance capacity observed in our model. Mechanistically, the upregulation of MerTK and subsequent enhancement of phagocytosis may be driven by specific metabolic and transcriptional sensors activated by FGF21. Previous studies have established that FGF21 can suppress inflammatory responses by modulating macrophage activation through the PPAR-γ signaling pathway.37 Given that PPAR-γ serves as a master transcriptional regulator known to induce the expression of scavenger and phagocytic receptors—including MerTK—it is highly plausible that the sustained release of FGF21 from our engineered MSCs activates the PPAR-γ axis in macrophages. Furthermore, FGF21 is known to activate the AMPK/SIRT1 pathway, which similarly promotes macrophage polarization toward a resolving, highly phagocytic phenotype. Therefore, we postulate that FGF21-MSCs reprogram the hepatic microenvironment by upregulating MerTK via FGF21-dependent metabolic pathways (such as PPAR-γ or AMPK/SIRT1), thereby equipping macrophages with the necessary machinery to efficiently clear necrotic debris and orchestrate liver repair following APAP hepatotoxicity. Accordingly, future studies that include crosstalk between macrophages and apoptotic hepatocytes or necrotic debris will be needed to further elucidate the roles, mechanisms, and therapeutic potential of phagocytosis in APAP-induced liver injury. Here, we report for the first time that pre-injection or post-injection of FGF21-MSCs rapidly reduced liver injury and reduced several mediators of inflammation. These results strongly support that a critical role of FGF21-MSCs in mediating macrophage-driven liver repair after APAP hepatotoxicity. We further showed that FGF21-MSCs accelerate inflammation resolution, possibly by enhanced macrophage phagocytosis of necrotic cell debris. However, the underlying molecular mechanism remains unclear and requires further investigation in subsequent studies. In addition, we have only validated the therapeutic potential of FGF21-MSCs in mice with APAP-induced ALI. Their therapeutic and application potential in other toxicant/drug-induced liver injuries remains unvalidated, which is the next step requiring clarification. In conclusion, we demonstrate a novel cell-based immunotherapeutic approach to facilitate necrosis resolution and promote tissue repair in experimental APAP-induced liver injury. Our findings showed that FGF21-MSCs provided sustained release of FGF21, which influenced macrophage functional phenotypic shift by activating phagocytic capacity for clearance of necrotic debris. Moreover, FGF21-MSCs enhanced the activity of antioxidant enzymes and reduced the activity of oxidase, contributing to the restoration of enzymatic homeostasis and ultimately promoting tissue repair. These findings offer novel insights into the role of FGF21-MSCs in the pathogenesis of ALI and may shed light on the development of MSC-based therapies ameliorating APAP-induced ALI. Supplementary Material